Sitagliptin Phosphate Monohydrate CAS 654671-77-9 Mimo>99.0% (HPLC) API Didara Giga Factory
Ipese Sitagliptin Phosphate Monohydrate Awọn agbedemeji ibatan:
Sitagliptin API CAS 486460-32-6
Sitagliptin Phosphate Monohydrate API CAS 654671-77-9
2,4,5-Trifluorophenylacetic Acid CAS 209995-38-0
Boc-(R) -3-Amino-4- (2,4,5-Trifluoro-Phenyl) -Butyric Acid CAS 486460-00-8
Sitagliptin Triazole Hydrochloride CAS 762240-92-6
Sitagliptin Phosphate Monohydrate Agbedemeji CAS 486460-21-3
Orukọ Kemikali | Sitagliptin Phosphate Monohydrate |
Awọn itumọ ọrọ sisọ | (R) -3-amino-1- (3- (trifluoromethyl) -5,6-dihydro- [1,2,4] triazolo [4,3-a] pyrazin-7 (8H) -yl)-4- (2,4,5-trifluorophenyl) butan-1-ọkan fosifeti monohydrate |
Nọmba CAS | 654671-77-9 |
Iṣura Ipo | Ninu Iṣura, Iwọn iṣelọpọ Ti o to Awọn Toonu |
Fọọmu Molecular | C16H20F6N5O6P |
Òṣuwọn Molikula | 523.3240802 |
Ojuami Iyo | 202.0 ~ 204.0 ℃ |
Omi Solubility | Tiotuka ninu Omi |
Yiyi pato | -18.0°~-23.0° (C=1, Omi) |
Brand | Ruifu Kemikali |
Nkan | Awọn pato |
Ifarahan | Funfun lati Pa-White Crystalline Powder |
Idanimọ nipa HPLC | Akoko idaduro ti ayẹwo jẹ ibamu pẹlu boṣewa itọkasi |
IR-infurarẹẹdi julọ.Oniranran | Spectrum Absorption IR ti ayẹwo yoo jẹ ibamu pẹlu ti iwoye boṣewa |
Phosphate | Ibamu |
Mimọ / Analysis Ọna | > 99.0% (HPLC lori ipilẹ ti o gbẹ) |
Akoonu Omi (KF) | 3.3% ~ 4.4% |
Aloku lori Iginisonu | ≤0.20% |
Sulfate | ≤0.02% |
Kloride | ≤0.05% |
Chiral Aimọ | <0.50% |
Awọn nkan ti o jọmọ | |
Aimọ Kanṣoṣo | <0.50% |
Lapapọ Awọn Aimọ | <1.0% |
Ethyl acetate | <0.50% |
Awọn irin Heavy | <20ppm |
Igbeyewo Standard | Standard Enterprise |
Lilo | elegbogi Intermediates |
Package: Igo, apo apamọwọ Aluminiomu, 25kg / Paali Drum, tabi gẹgẹbi ibeere alabara.
Ipò Ìpamọ́:Fipamọ sinu awọn apoti ti a fi edidi ni itura ati ibi gbigbẹ;Dabobo lati ina ati ọrinrin.
Sitagliptin Phosphate Monohydrate (CAS: 654671-77-9), oogun tuntun fun itọju iru àtọgbẹ 2.Ni Oṣu Kẹjọ ọdun 2009, oogun naa ti fọwọsi nipasẹ European Union bi oogun laini akọkọ fun itọju iru àtọgbẹ 2.Sitagliptin Phosphate ni akọkọ FDA-fọwọsi dipeptidyl peptidase-IV inhibitor lati ṣee lo ninu itọju iru àtọgbẹ 2 jina, labẹ orukọ iṣowo Januvia.Dipeptidylpeptidase Ⅳ (DPP-Ⅳ) ni iyara ati imunadoko dinku GLP-1, GLP-1, eyiti o jẹ oludasiṣẹ ti o munadoko julọ ti iṣelọpọ hisulini ati yomijade Nitorinaa, idinamọ DPP-IV le mu ipa ti GLP-1 endogenous pọ si, nitorinaa jijẹ ẹjẹ pọ si. awọn ipele hisulini, nitorinaa idinku ati ṣetọju awọn ipele glukosi ẹjẹ ni awọn alaisan ti o ni àtọgbẹ.Lọwọlọwọ, oogun ti jẹrisi pe oludena DPP-IV jẹ oriṣi tuntun ti oogun egboogi-diabetic, ati awọn abajade ile-iwosan fihan pe awọn oogun naa ni ipa hypoglycemic to dara.Nitori GLP-1 ṣe ipa ti o gbẹkẹle glukosi ni igbega iṣelọpọ hisulini ati yomijade, awọn aati ikolu ti o wọpọ gẹgẹbi hypoglycemia ati ere iwuwo ti o ṣẹlẹ nipasẹ lilo awọn oogun antidiabetic ko waye.